1+ day, 13+ hour ago   (407+ words) Proteomic fragmentation may explain reduced allergenicity and point to a safer substrate for peanut oral immunotherapy compared with current options, new data suggests. A new study showed that autoclaving peanuts breaks down major allergens, significantly lowering IgE binding, skin test…...

2+ day, 2+ hour ago   (51+ words) Autoclaving Peanuts May Reduce Allergenicity'HCPLive Tips on Billing Issues in Dermatology Practices, With Daniel Siegel, MD Cutaneous Oncology Updates for 2026, With Paul Nghiem, MD, PhD Preparation Before Psychedelics Tied to Better MDD, With Gianluca Florineth, MSc Erectile Dysfunction as a…...

1+ week, 3+ day ago   (605+ words) Upton discusses an open-label trial showing a 30 mg per nut very low-dose oral immunotherapy strategy increased multi-nut tolerance and remained safe in children. A recent open-label study suggests that very low'dose oral immunotherapy (VLOIT) can both meaningfully and safely increase…...

2+ week, 5+ day ago   (1072+ words) An 18-month study of children with up to 5 nut allergies found that a 30-mg per-nut maintenance dose significantly improved tolerated doses without serious adverse events. A recent study showed that very low-dose oral immunology (VLOIT) significantly increased tolerated doses of…...

2+ week, 5+ day ago   (1018+ words) A study found tahini was associated with lower reaction thresholds and higher anaphylaxis rates than whole seeds, suggesting it may better reflect true sesame allergy risk. In a recent study, outcomes of 307 pediatric sesame oral food challenges (OFC) varied by…...

3+ week, 1+ day ago   (961+ words) Q4 2025 brought key FDA approvals and phase 3 advances in HAE, peanut allergy, multi-allergen immunotherapy, and allergic fungal rhinosinusitis. In this recap, we spotlighted 8 allergy news stories published between October through December. The FDA approved berotralstat (ORLADEYO) oral pellets for children aged…...

3+ week, 4+ day ago   (247+ words) December highlights: FDA approval of berotralstat for pediatric HAE, phase 3 RAPIDe-3 results, and allergy field spotlights in our This Year in Medicine series. For clinicians, December's updates underscore a broader shift toward more personalized, less burdensome care, particularly for pediatric…...